Clinical trial
A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human…
NCT00211042 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00211042 |
|---|---|
| Title | A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment |
| Official title | Observational, Multicenter Study of Subjects With Pure Red Cell Aplasia Associated With r-HuEPO Treatment |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pure Red-cell Aplasia |
| Intervention type | Other |
| Interventions | No intervention |
| Enrollment | 52 |
| Start date | Feb 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Apr 30, 2013 |
| Countries | Brazil, Canada, Germany, Norway, South Africa, Sweden, Thailand, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: